281 related articles for article (PubMed ID: 26350436)
21. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
22. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
23. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
24. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.
Kuro-o M
Nat Rev Nephrol; 2013 Nov; 9(11):650-60. PubMed ID: 23774819
[TBL] [Abstract][Full Text] [Related]
25. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
26. Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease.
Saxena A; Sachan T; Gupta A; Kapoor V
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014808
[TBL] [Abstract][Full Text] [Related]
27. FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan.
Balmukhanova A; Kabulbayev K; Alpay H; Kanatbayeva A; Balmukhanova A
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33379157
[No Abstract] [Full Text] [Related]
28. Niacin and Chronic Kidney Disease.
Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
[TBL] [Abstract][Full Text] [Related]
29. Role of Klotho in aging, phosphate metabolism, and CKD.
John GB; Cheng CY; Kuro-o M
Am J Kidney Dis; 2011 Jul; 58(1):127-34. PubMed ID: 21496980
[TBL] [Abstract][Full Text] [Related]
30. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease.
Cozzolino M; Mazzaferro S
Curr Vasc Pharmacol; 2010 May; 8(3):404-11. PubMed ID: 20180772
[TBL] [Abstract][Full Text] [Related]
31. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
32. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
33. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast Growth Factor-23: A Novel Biomarker for Cardiovascular Disease in Chronic Kidney Disease Patients.
Papagianni A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):19-27. PubMed ID: 28991773
[TBL] [Abstract][Full Text] [Related]
35. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
36. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Quiñones H; Hamdi T; Sakhaee K; Pasch A; Moe OW; Pak CYC
J Nephrol; 2019 Feb; 32(1):93-100. PubMed ID: 30465137
[TBL] [Abstract][Full Text] [Related]
37. The Importance of Phosphate Control in Chronic Kidney Disease.
Tsuchiya K; Akihisa T
Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
[TBL] [Abstract][Full Text] [Related]
38. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
Seiler S; Rogacev KS; Roth HJ; Shafein P; Emrich I; Neuhaus S; Floege J; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1049-58. PubMed ID: 24677555
[TBL] [Abstract][Full Text] [Related]
39. [Phosphorus: a new cardiovascular risk factor?].
Insalaco M; Scuderi R; Zanoli L; Galeano D; Failla A; Fatuzzo P; Granata A
Clin Ter; 2015; 166(6):e389-400. PubMed ID: 26794822
[TBL] [Abstract][Full Text] [Related]
40. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.
Quarles LD
Exp Cell Res; 2012 May; 318(9):1040-8. PubMed ID: 22421513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
